Intellia says Phase 3 HAELO trial shows 87% attack reduction with lonvo-z in hereditary angioedema

Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc.

NTLA

0.00
  • Intellia Therapeutics presented additional Phase 3 HAELO data on lonvo-z for hereditary angioedema at the EAACI Annual Congress 2026.
  • Results were simultaneously published in the New England Journal of Medicine, extending previously disclosed topline findings.
  • Lonvo-z reduced attack burden versus placebo, with many patients remaining free of attacks and off preventive therapy during the evaluation period.
  • Quality-of-life outcomes improved versus placebo, supporting a clinically meaningful benefit for patients.
  • A rolling BLA submission began in April, with U.S. approval and launch targeted for the first half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-270358), on June 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.